Genetic dissection of strain dependent paraquat-induced neurodegeneration in the substantia nigra pars compacta

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Jiao, Yun ^a   Lu, Lu ^b   Williams, Robert W ^b   Smeyne, Richard J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; PARAQUAT; HERBICIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CHROMOSOMAL LOCALIZATION; CHROMOSOME 14; CHROMOSOME 5; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISSECTION; LINKAGE ANALYSIS; MALE; MOUSE; NERVE CELL; NERVE DEGENERATION; NONHUMAN; QUANTITATIVE TRAIT LOCUS MAPPING; SPECIES DIFFERENCE; SUBSTANTIA NIGRA PARS COMPACTA; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DOPAMINERGIC NERVE CELL; DRUG EFFECT; EVALUATION; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MICROARRAY ANALYSIS; PATHOLOGY; SUBSTANTIA NIGRA;

MUS; PARKINSONIA;

ANIMALS; DOPAMINERGIC NEURONS; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HERBICIDES; MALE; MICE; MICE, INBRED C57BL; MICROARRAY ANALYSIS; NERVE DEGENERATION; PARAQUAT; SPECIES SPECIFICITY; SUBSTANTIA NIGRA;

EID: 84856141898     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029447     Document Type: Article

References (68)

1. Duvoisin RC, (1999) Genetic and environmental factors in Parkinson's disease. Advances in Neurology 80: 161-163.
2. Gasser T, (2001) Genetics of Parkinson's disease. J Neurol 248: 833-840.
3. Williams AC, Smith ML, Waring RH, Ramsden DB, (1999) Idiopathic Parkinson's disease: a genetic and environmental model. Advances in Neurology 80: 215-218.
4. Payami H, Zareparsi S, (1998) Genetic epidemiology of Parkinson's disease. Journal of Geriatric Psychiatry & Neurology 11: 98-106.
5. Jenner P, (2003) Oxidative stress in Parkinson's disease. Ann Neurol 53 (Suppl 3): S26-36; discussion S36-28.
6. Przedborski S, Jackson-Lewis V, Vila M, Wu du C, Teismann P, et al. (2003) Free radical and nitric oxide toxicity in Parkinson's disease. Adv Neurol 91: 83-94.
7. Richardson JR, Quan Y, Sherer TB, Greenamyre JT, Miller GW, (2005) Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicol Sci 88: 193-201.
8. Bonneh-Barkay D, Reaney SH, Langston WJ, Di Monte DA, (2005) Redox cycling of the herbicide paraquat in microglial cultures. Mol Brain Res 134: 52-56.
9. Yumino K, Kawakami I, Tamura M, Hayashi T, Nakamura M, (2002) Paraquat- and diquat-induced oxygen radical generation and lipid peroxidation in rat brain microsomes. J Biochem (Tokyo) 131: 565-570.
10. Mitra N, Mohanakumar KP, Ganguly DK, (1994) Resistance of golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship with low levels of regional monoamine oxidase B. Journal Of Neurochemistry 62: 1906-1912.
11. Riachi NJ, Harik SI, (1988) Strain differences in systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice correlate best with monoamine oxidase activity at the blood-brain barrier. Life Sci 42: 2359-2363.
12. Sundstrom E, Stromberg I, Tsutsumi T, Olson L, Jonsson G, (1987) Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catacholamine neurons in C57Bl/6 mice. Comparison with three other strains of mice. Brain Res 405: 26-38.
13. Williams RW, (1998) Neuroscience meets quantitative genetics: Using Morphometric data to map genes that modulate CNS architecture. Nervenet Website, available at: http://www.nervenet.org/papers/shortcourse98.html. Last viewed Nov. 30, 2011.
14. Crusio W, (1992) Quantitative genetics. In: Goldowitz DWD, Wimer RE, editors. Techniques for the genetic analysis of brain and behavior Amsterdam Elsevier pp. 231-250.
15. Cook R, Lu L, Gu J, Williams RW, Smeyne RJ, (2003) Identification of a single QTL, Mptp1, for susceptibility to MPTP-induced substantia nigra pars compacta neuron loss in mice. Brain Res Mol Brain Res 110: 279-288.
16. Baquet ZC, Williams D, Brody J, Smeyne RJ, (2009) A comparison of model-based (2D) and design-based (3D) stereological methods for estimating cell number in the substantia nigra pars compacta (SNpc) of the C57BL/6J Mouse. Neuroscience 161: 1082-1090.
17. Manly KF, Cudmore RH Jr, Meer JM, (2001) Map Manager QTX, cross-platform software for genetic mapping. Mamm Genome 12: 930-932.
18. Paxinos G, Franklin KBJ, (2001) The Mouse Brain in Stereotaxic Coordinates San Diego Academic Press.
19. Hamre K, Tharp R, Poon K, Xiong X, Smeyne RJ, (1999) Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus. Brain Res 828: 91-103.
20. Yin L, Lu L, Prasad K, Richfield EK, Unger EL, et al. (2011) Genetic-based, differential susceptibility to paraquat neurotoxicity in mice. Neurotoxicol Teratol 33: 415-421.
21. Sonsalla PK, Heikkila RE, (1988) Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and methamphetamine in several strains of mice. Prog Neuropsychopharmacol Biol Psychiatry 12: 345-354.
22. Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, et al. (2000) Evidence for resistance to MPTP in C57BL/6×BALB/c F1 hybrids as compared with their progenitor strains. Neuroreport 11: 1093-1096.
23. Smeyne M, Goloubeva O, Smeyne RJ, (2001) Strain-dependent susceptibility to MPTP and MPP+-induced Parkinsonism is determined by glia. Glia 74: 73-80.
24. Peter B, Wartena M, Kampinga HH, Konings AW, (1992) Role of lipid peroxidation and DNA damage in paraquat toxicity and the interaction of paraquat with ionizing radiation. Biochem Pharmacol 43: 705-715.
25. Cocheme HM, Murphy MP, (2008) Complex I is the major site of mitochondrial superoxide production by paraquat. J Biol Chem 283: 1786-1798.
26. Fukushima T, Yamada K, Hojo N, Isobe A, Shiwaku K, et al. (1994) Mechanism of cytotoxicity of paraquat. III. The effects of acute paraquat exposure on the electron transport system in rat mitochondria. Exp Toxicol Pathol 46: 437-441.
27. Shimizu K, Ohtaki K, Matsubara K, Aoyama K, Uezono T, et al. (2001) Carrier-mediated processes in blood-brain barrier penetration and neural uptake of paraquat. Brain Res 906: 135-142.
28. Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B, (2009) Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol 169: 919-926.
29. Dhillon AS, Tarbutton GL, Levin JL, Plotkin GM, Lowry LK, et al. (2008) Pesticide/environmental exposures and Parkinson's disease in East Texas. J Agromedicine 13: 37-48.
30. Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, et al. (2011) Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect 119: 866-872.
31. Liou HH, Chen RC, Tsai YF, Chen WP, Chang YC, et al. (1996) Effects of paraquat on the substantia nigra of the wistar rats: neurochemical, histological, and behavioral studies. Toxicol Appl Pharmacol 137: 34-41.
32. Peng J, Mao XO, Stevenson FF, Hsu M, Andersen JK, (2004) The herbicide paraquat induces dopaminergic nigral apoptosis through sustained activation of the JNK pathway. J Biol Chem 279: 32626-32632 Epub 32004 May 32620.
33. Damier P, Kastner A, Agid Y, Hirsch EC, (1996) Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease? Neurology 46: 1262-1269.
34. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, et al. (2000) Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 20: 6309-6316.
35. Andersen JK, (2001) Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease? Novartis Found Symp 235: 11-20; discussion 20-15.
36. Ethell DW, Fei Q, (2009) Parkinson-linked genes and toxins that affect neuronal cell death through the Bcl-2 family. Antioxid Redox Signal 11: 529-540.
37. Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, et al. (2009) Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 124: 593-605.
38. Simon-Sanchez J, van Hilten JJ, van de Warrenburg B, Post B, Berendse HW, et al. (2011) Genome-wide association study confirms extant PD risk loci among the Dutch. Eur J Hum Genet 19: 655-661.
39. Dutheil F, Jacob A, Dauchy S, Beaune P, Scherrmann JM, et al. (2010) ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders. Expert Opin Drug Metab Toxicol 6: 1161-1174.
40. Shahabi HN, Andersson DR, Nissbrandt H, (2008) Cytochrome P450 2E1 in the substantia nigra: relevance for dopaminergic neurotransmission and free radical production. Synapse 62: 379-388.
41. Denhardt DT, Guo X, (1993) Osteopontin: a protein with diverse functions. Faseb J 7: 1475-1482.
42. Iczkiewicz J, Jackson MJ, Smith LA, Rose S, Jenner P, (2006) Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease. Brain Res 1118: 239-250.
43. Maetzler W, Berg D, Schalamberidze N, Melms A, Schott K, et al. (2007) Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol Dis 25: 473-482.
44. Seidel K, Vinet J, den Dunnen WF, Brunt ER, Meister M, et al. (2011) The HSPB8-BAG3 chaperone complex is upregulated in astrocytes in the human brain affected by protein aggregation diseases. Neuropathol Appl Neurobiol.
45. Bruinsma IB, Bruggink KA, Kinast K, Versleijen AAM, Segers-Nolten IMJ, et al. (2011) Inhibition of α-synuclein aggregation by small heat shock proteins Proteins Structure, Function, and Bioinformatics: n/a-n/a.
46. Duda JE, Lee VM, Trojanowski JQ, (2000) Neuropathology of synuclein aggregates. J Neurosci Res 61: 121-127.
47. Lavoinne A, Buc HA, Claeyssens S, Pinosa M, Matray F, (1987) The mechanism by which adenosine decreases gluconeogenesis from lactate in isolated rat hepatocytes. Biochem J 246: 449-454.
48. Lund P, Cornell NW, Krebs HA, (1975) Effect of adenosine on the adenine nucleotide content and metabolism of hepatocytes. Biochem J 152: 593-599.
49. Chan CS, Gertler TS, Surmeier DJ, (2010) A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease. Mov Disord 25 (Suppl 1): S63-70.
50. Vali S, Mythri RB, Jagatha B, Padiadpu J, Ramanujan KS, et al. (2007) Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: a dynamic model. Neuroscience 149: 917-930.
51. Polli JW, Billingsley ML, Kincaid RL, (1991) Expression of the calmodulin-dependent protein phosphatase, calcineurin, in rat brain: developmental patterns and the role of nigrostriatal innervation. Brain Res Dev Brain Res 63: 105-119.
52. Simpkins JW, Yi KD, Yang SH, (2009) Role of protein phosphatases and mitochondria in the neuroprotective effects of estrogens. Front Neuroendocrinol 30: 93-105.
53. Yi KD, Cai ZY, Covey DF, Simpkins JW, (2008) Estrogen receptor-independent neuroprotection via protein phosphatase preservation and attenuation of persistent extracellular signal-regulated kinase 1/2 activation. J Pharmacol Exp Ther 324: 1188-1195.
54. Gross RE, Mei Q, Gutekunst CA, Torre E, (2007) The pivotal role of RhoA GTPase in the molecular signaling of axon growth inhibition after CNS injury and targeted therapeutic strategies. Cell Transplant 16: 245-262.
55. Sanchez M, Gastaldi L, Remedi M, Caceres A, Landa C, (2008) Rotenone-induced toxicity is mediated by Rho-GTPases in hippocampal neurons. Toxicol Sci 104: 352-361.
56. Rampon C, Jiang CH, Dong H, Tang YP, Lockhart DJ, et al. (2000) Effects of environmental enrichment on gene expression in the brain. Proc Natl Acad Sci U S A 97: 12880-12884.
57. Faherty CJ, Raviie Shepherd K, Herasimtschuk A, Smeyne RJ, (2005) Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism. Brain Res Mol Brain Res 134: 170-179.
58. Brzozowski MJ, Alcantara SL, Iravani MM, Rose S, Jenner P, (2011) The effect of nNOS inhibitors on toxin-induced cell death in dopaminergic cell lines depends on the extent of enzyme expression. Brain Res 1404: 21-30.
59. Gogvadze E, Buzdin A, (2009) Retroelements and their impact on genome evolution and functioning. Cell Mol Life Sci 66: 3727-3742.
60. Korneev SA, Park JH, O'Shea M, (1999) Neuronal expression of neural nitric oxide synthase (nNOS) protein is suppressed by an antisense RNA transcribed from an NOS pseudogene. J Neurosci 19: 7711-7720.
61. Werner A, Carlile M, Swan D, (2009) What do natural antisense transcripts regulate? RNA Biol 6: 43-48.
62. Pavlicek A, Gentles AJ, Paces J, Paces V, Jurka J, (2006) Retroposition of processed pseudogenes: the impact of RNA stability and translational control. Trends Genet 22: 69-73.
63. Townsend DM, Tew KD, (2003) The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22: 7369-7375.
64. Hayes KR, Young BM, Pletcher MT, (2009) Expression quantitative trait loci mapping identifies new genetic models of glutathione S-transferase variation. Drug Metab Dispos 37: 1269-1276.
65. Beiswanger CM, Diegmann MH, Novak RF, Philbert MA, Graessle TL, et al. (1995) Developmental changes in the cellular distribution of glutathione and glutathione S-transferases in the murine nervous system. Neurotoxicology 16: 425-440.
66. Smeyne M, Boyd J, Raviie Shepherd K, Jiao Y, Pond BB, et al. (2007) GSTpi expression mediates dopaminergic neuron sensitivity in experimental parkinsonism. Proc Natl Acad Sci U S A 104: 1977-1982.
67. Dagnino-Subiabre A, Cassels BK, Baez S, Johansson AS, Mannervik B, et al. (2000) Glutathione transferase M2-2 catalyzes conjugation of dopamine and dopa o-quinones. Biochem Biophys Res Commun 274: 32-36.
68. Smeyne RJ, Jackson-Lewis V, (2005) The MPTP model of Parkinson's disease. Brain Res Mol Brain Res 134: 57-66.